Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo

Molecular and Cellular Neuroscience

Volumn 48, Issue 1, 2011, Pages 72-81

  Hu, Yinghui ^a   Lee, Xinhua ^a   Ji, Benxiu ^a   Guckian, Kevin ^a   Apicco, Daniel ^a   Pepinsky, R Blake ^a   Miller, Robert H ^b   Mi, Sha ^a  

^a BIOGEN   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FTY720; Oligodendrocyte; Remyelination

Indexed keywords

CUPRIZONE; FINGOLIMOD; LYSOPHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNOLOGY; IMMUNOMODULATION; IN VIVO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; REMYELINIZATION;

ANIMALS; CHELATING AGENTS; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MYELIN SHEATH; NERVE REGENERATION; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

ANIMALIA;

EID: 79960895505     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2011.06.007     Document Type: Article

References (28)

1. Al-lzki S., Pryce G., Jackson S.J., Giovannoni G., Baker D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmue encephalomyelitis. Mult. Scle. J. 2011, 1-10.
2. Bradl M., Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol. 2010, 119:37-53.
3. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., Aradhye S., Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
4. Choi J.W., Gardell S.E., Herr D.R., Rivera R., Lee C.W., Noguchi K., Teo S.T., Yung Y.C., Lu M., Kennedy G., Chun J. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:751-756.
5. Cohen B.A., Rieckmann P. Emerging oral therapies for multiple sclerosis. Int. J. Clin. Pract. 2007, 61:1922-1930.
6. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de Vera A., Jin J., Stites T., Wu S., Aradhye S., Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
7. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
8. Foster C.A., Howard L.M., Schweitzer A., Persohn E., Hiestand P.C., Balatoni B., Reuschel R., Beerli C., Schwartz M., Billich A. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 2007, 323:469-475.
9. Furlan R., Cuomo C., Martino G. Animal models of multiple sclerosis. Methods Mol. Biol. 2009, 549:157-173.
10. Harada J., Foley M., Moskowitz M.A., Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 2004, 88:1026-1039.
11. Hemmer B., Hartung H.P. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. Ann. Neurol. 2007, 62:314-326.
12. Jaillard C., Harrison S., Stankoff B., Aigrot M.S., Calver A.R., Duddy G., Walsh F.S., Pangalos M.N., Arimura N., Kaibuchi K., Zalc B., Lubetzki C. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 2005, 25:1459-1469.
13. Jung C., Kim H., Miron V., Cook S., Kennedy T., Foster C., Antel J., Soliven B. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007, 55:1656-1667.
14. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., Radue E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 355:1124-1140.
15. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
16. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., Chiba K. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005, 2:439-448.
17. Kim H.J., Miron V.E., Dukala D., Proia R.L., Ludwin S.K., Traka M., Antel J.P., Soliven B. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J. 2011, 25:1509-1518.
18. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., Wong W.M., Wang L., Su H., Chu T.H., Guo J., Zhang W., So K.F., Pepinsky B., Shao Z., Graff C., Garber E., Jung V., Wu E.X., Wu W. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
19. Mi S., Miller R.H., Tang W., Lee X., Hu B., Wu W., Zhang Y., Shields C.B., Zhang Y., Miklasz S., Shea D., Mason J., Franklin R.J., Ji B., Shao Z., Chedotal A., Bernard F., Roulois A., Xu J., Jung V., Pepinsky B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 2009, 65:304-315.
20. Miller R.H., Mi S. Dissecting demyelination. Nat. Neurosci. 2007, 10:1351-1354.
21. Miron V., Jung C., Kim H., Kennedy T., Soliven B., Antel J. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 2008, 63:61-71.
22. Miron V.E., Schubart A., Antel J.P. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008, 274:13-17.
23. Miron V.E., Ludwin S.K., Darlington P.J., Jarjour A.A., Soliven B., Kennedy T.E., Antel J.P. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 2010, 176:2682-2694.
24. Narayanan S.P., FLores A.I., Wang F., Macklin W.B. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J. Neurosci. 2009, 29:6860-6870.
25. O'Connor P., Comi G., Montalban X., Antel J., Radue E.W., de Vera A., Pohlmann H., Kappos L. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009, 72:73-79.
26. Papadopoulos D., Rundle J., Patel R., Marshall I., Stretton J., Eaton R., Richardson J.C., Gonzalez M.I., Philpott K.L., Reynolds R. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J. Neurosci. Res. 2010, 88:346-359.
27. Pébay A., Toutant M., Prémont J., Calvo C.-F., Venance L., Cordier J., Glowinski J., Tencé M. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur. J. Neurosci. 2001, 13:2067-2076.
28. Rau R.C., Hein K., Sattler B.M., Kretzschmar B., Hillgruber C., McRae L.B., Diem R., Bahr M. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. Neurobio. 2011, 178:1770-1781.